DB
ENVB icon

Danske Bank’s Enveric Biosciences ENVB Stock Holding History

Danske Bank’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2 Hold
1
– – ﹤0.01% 1140
2025
Q4 		$4 Buy
+1
New +$7 ﹤0.01% 1511

Other funds holding ENVB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Danske Bank's ENVB Position: Q1 2026 in Review

Danske Bank held its Enveric Biosciences (ENVB) position steady in Q1 2026 at 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #1140.

Danske Bank first reported a position in ENVB in Q4 2025 and has held it in 2 quarters since. The position peaked at $4 in Q4 2025. 11 funds tracked by Wall St. Rank hold ENVB as of Q1 2026.

  • Danske Bank held 1 share of Enveric Biosciences worth $2 as of Q1 2026.
  • Danske Bank left its Enveric Biosciences share count unchanged in Q1 2026.
  • Enveric Biosciences made up ﹤0.01% of Danske Bank's portfolio in Q1 2026, its #1140 holding.
  • Danske Bank first reported a position in Enveric Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Danske Bank's Enveric Biosciences position peaked at $4 in Q4 2025.
  • 11 funds tracked by Wall St. Rank held Enveric Biosciences as of Q1 2026.

Based on Danske Bank's 13F filing for Q1 2026, filed 12 May 2026.